Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

MoeMaze Jun. 1 at 6:14 AM

$BCTX !!!!!

0 · Reply

MoeMaze Jun. 1 at 6:09 AM

$BCTX 🔁🤢🔁

0 · Reply

MoeMaze Jun. 1 at 6:03 AM

$BCTX as expected ! #Crooks !

1 · Reply

letsdodiz Jun. 1 at 5:08 AM

$BCTX This is why we saw the 25% drop 2 Fridays back but raise seems modest and without warrants...a first.

0 · Reply

shonv Jun. 1 at 4:07 AM

$BCTX Maybe tomorrow will be a Red day but will be back

0 · Reply

kysung0213 Jun. 1 at 4:02 AM

$BCTX Are we free from dilution till the interim data readout ? Good product will speak itself !

1 · Reply

shonv Jun. 1 at 3:43 AM

$BCTX Over night we r down almost 12% but still i m optimistic and bullish ab the development

1 · Reply

TopCharts Jun. 1 at 3:33 AM

$BCTX Sunday offering gotta love this company 😂

1 · Reply

focafoca99 Jun. 1 at 3:12 AM

$BCTX priced its best‑efforts offering at $3.25 per share, targeting about $4.7 million in gross proceeds.

0 · Reply

Peterman25 Jun. 1 at 1:26 AM

$BCTX Goes to show you how much they don’t buy their own product. So, not a buy signal yet. Or did any of them participate in this offering? Allow me to decipher this “Maintenance Offering” - just aligning things for the next reverse split.

1 · Reply

BriaCell Therapeutics Announces Pricing of Offering

2026-05-26T14:43:01.000Z - 5 days ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T13:05:39.000Z - 5 days ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

Tue, 26 May 2026 07:30:00 -0400 - 5 days ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-05-22T13:27:19.000Z - 9 days ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T11:49:02.000Z - 9 days ago

BriaCell announces data from Bria-IMT at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 9 days ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 15 May 2026 07:30:00 -0400 - 16 days ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 17 days ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 17 days ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 18 days ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 18 days ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 18 days ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 19 days ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 24 days ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 25 days ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 25 days ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 5 weeks ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 5 weeks ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 5 weeks ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 5 weeks ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 2 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 2 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 2 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 3 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 3 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 3 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Wed, 18 Feb 2026 17:30:00 -0500 - 3 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 3 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

Tue, 17 Feb 2026 07:30:00 -0500 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T12:40:40.000Z - 4 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Wed, 28 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 4 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T12:41:04.000Z - 4 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Tue, 27 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 4 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 4 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 4 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 4 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 4 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T20:32:32.000Z - 4 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T14:41:11.000Z - 4 months ago

BriaCell Therapeutics trading resumes

2026-01-13T14:35:29.000Z - 4 months ago

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T12:35:49.000Z - 4 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

Jan 13, 2026, 7:30 AM EST - 4 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Dec 18, 2025, 7:30 AM EST - 5 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T12:41:29.000Z - 6 months ago

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

Dec 10, 2025, 7:30 AM EST - 6 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

2025-12-09T12:35:35.000Z - 6 months ago

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

Dec 9, 2025, 7:30 AM EST - 6 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

2025-12-02T12:36:29.000Z - 6 months ago

BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025

Dec 2, 2025, 7:30 AM EST - 6 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 6 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

2025-11-20T12:40:35.000Z - 6 months ago

BriaCell, Receptor.AI collaborate on AI small molecular cancer therapeutics

Nov 20, 2025, 7:30 AM EST - 6 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 6 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 7 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 7 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 21, 2025, 7:50 AM EDT - 7 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 7 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 7 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 8 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 8 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 9 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 9 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 10 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 10 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 10 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 10 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 10 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 11 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 11 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 11 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 11 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 11 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 11 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 11 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

MoeMaze Jun. 1 at 6:14 AM

$BCTX !!!!!

0 · Reply

MoeMaze Jun. 1 at 6:09 AM

$BCTX 🔁🤢🔁

0 · Reply

MoeMaze Jun. 1 at 6:03 AM

$BCTX as expected ! #Crooks !

1 · Reply

letsdodiz Jun. 1 at 5:08 AM

$BCTX This is why we saw the 25% drop 2 Fridays back but raise seems modest and without warrants...a first.

0 · Reply

shonv Jun. 1 at 4:07 AM

$BCTX Maybe tomorrow will be a Red day but will be back

0 · Reply

kysung0213 Jun. 1 at 4:02 AM

$BCTX Are we free from dilution till the interim data readout ? Good product will speak itself !

1 · Reply

shonv Jun. 1 at 3:43 AM

$BCTX Over night we r down almost 12% but still i m optimistic and bullish ab the development

1 · Reply

TopCharts Jun. 1 at 3:33 AM

$BCTX Sunday offering gotta love this company 😂

1 · Reply

focafoca99 Jun. 1 at 3:12 AM

$BCTX priced its best‑efforts offering at $3.25 per share, targeting about $4.7 million in gross proceeds.

0 · Reply

Peterman25 Jun. 1 at 1:26 AM

1 · Reply

TWBXX Jun. 1 at 1:13 AM

$BCTX Executive Board Ownership Summary Insider / Executive Shares % of Company Richard Abbe (Director) 104,000 1.43% Dr. William Williams (CEO) 35,218 0.49% Dr. Giuseppe Del Priore (CMO) 18,839 0.26% Gadi Levin (CFO) 9,438 0.13% Dr. Miguel Lopez‑Lago (CSO) 9,419 0.13% Jeremy Plambeck (Board) 4,330 0.06% Vaughn Embro‑Pantalony (Board) 163 0.00%

1 · Reply

TWBXX Jun. 1 at 1:01 AM

$BCTX As Bud Fox said to Gordon Gekko in the movie Wall Street. There's only a small float out there you better grab it!

0 · Reply

TWBXX Jun. 1 at 12:41 AM

$BCTX The offering of 1,449,300 common shares takes us from 14 million fully diluted shares to 15,449,300 million, which is a minor increase in shares for maintenance purposes only per PR

0 · Reply

TWBXX Jun. 1 at 12:30 AM

$BCTX BCTX issuing 1.4M shares is basically a maintenance raise, not a structural change.

4 · Reply

TWBXX Jun. 1 at 12:19 AM

$BCTX BriaCell Therapeutics Announces Pricing of Offering BriaCell Therapeutics Corp. Sun, May 31, 2026 at 7:59 PM EDT 4 min read

0 · Reply

JediGreen May. 31 at 8:05 AM

$BCTX Any of you medical professionals see anything new yet?

1 · Reply

laaarsas May. 30 at 2:25 PM

$BCTX You believe in this ph3. Why?

2 · Reply

JediGreen May. 30 at 12:16 PM

$BCTX https://youtube.com/shorts/22kh8-SQZkM?si=55CJv-Wec2s1z0ce

0 · Reply

superguild May. 30 at 3:17 AM

$BCTX too bad we cant tie the dumb ass management's compensation to stock performance. Wonder how they would like it rolled back 150:1 in last year

0 · Reply

BHWinehouse May. 29 at 9:47 PM

$BCTX See you on Monday!

1 · Reply

JediGreen May. 29 at 7:10 AM

$BCTX

1 · Reply

JediGreen May. 29 at 7:10 AM

$BCTX briacell therapeutics phase 3 compared to standard of care - Google Search https://www.google.com/search?q=briacell+therapeutics+phase+3+compared+to+standard+of+care&sca_esv=8de72729b5786757&udm=50&aep=1&ntc=1&sa=X&ved=0ahUKEwiG5_GA992UAxUSGYYAHQ_iIL4Q2J8OCBk&biw=430&bih=721&dpr=3&mstk=AUtExfDMbMmw99tPWaRS7LnOH9mIDVxOV8-F-c_rdMWdWh93QQV4v_aE48-HSNOi-tliHwi06x1xeIEe1i7P_SQcDEw4d2_GQKj8NtFge8sg__DkIZJpt77MGp4pVs3IPLWzY2jNZQSoaZDHiN5d7LNKBYDNtZ8hyb7uK4k&csuir=1

0 · Reply

Market Cap	26.39M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	145,600
Avg Vol	203,346
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	62%
Beta	1.26
Analysts	Strong Buy
Price Target	$40.00